Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note published on Thursday,Benzinga reports. They currently have a $77.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also recently commented on the company. Oppenheimer reissued an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Cantor Fitzgerald upped their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday. Piper Sandler started coverage on Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price for the company. Finally, Maxim Group boosted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Up 0.6 %

Shares of CAPR opened at $18.61 on Thursday. The stock has a market cap of $845.01 million, a P/E ratio of -17.56 and a beta of 4.00. The business’s 50 day moving average price is $15.21 and its 200-day moving average price is $8.50. Capricor Therapeutics has a 52 week low of $2.87 and a 52 week high of $23.40.

Insider Transactions at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of Capricor Therapeutics stock in a transaction that occurred on Friday, September 20th. The stock was bought at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. The trade was a 65.21 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 12.00% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after acquiring an additional 200,499 shares during the period. State Street Corp boosted its stake in shares of Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after acquiring an additional 111,291 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Capricor Therapeutics during the third quarter worth about $3,806,000. PFM Health Sciences LP bought a new stake in Capricor Therapeutics during the 3rd quarter valued at approximately $2,324,000. Finally, Renaissance Technologies LLC lifted its holdings in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.